Literature DB >> 10827135

Signaling properties and functions of two distinct cardiomyocyte protease-activated receptors.

A Sabri1, G Muske, H Zhang, E Pak, A Darrow, P Andrade-Gordon, S F Steinberg.   

Abstract

Previous studies have established that cardiomyocytes express protease-activated receptor (PAR)-1, a high-affinity receptor for thrombin, which is also activated by the tethered-ligand domain sequence (SFLLRN) and which promotes inositol trisphosphate accumulation, stimulates extracellular signal-regulated protein kinase, and modulates contractile function. A single previous report identified PAR-1 as a hypertrophic stimulus, but there have been no subsequent investigations of the mechanism. This study reveals the coexpression of PAR-1 and PAR-2 (a second PAR, which is activated by trypsin/tryptase but not thrombin) by Northern blot analysis and compares their signaling properties in neonatal rat ventricular cardiomyocytes. SFLLRN and SLIGRL (an agonist peptide for PAR-2) promote inositol trisphosphate accumulation, stimulate mitogen-activated protein kinases (extracellular signal-regulated protein kinase and p38-mitogen-activated protein kinase), elevate calcium concentration, and increase spontaneous automaticity. SFLLRN (but not SLIGRL) also activates c-Jun NH(2)-terminal kinase and AKT. In keeping with their linkage to pathways that have been associated with growth and/or survival, SFLLRN and SLIGRL both induce hypertrophy. However, PAR agonists promote cell elongation, a morphology that is distinct from the uniform increase in cell dimension induced by alpha(1)-adrenergic receptor activation. These studies provide novel evidence that cardiomyocytes coexpress 2 functional PARs, which link to a common set of signals that culminate in changes in contractile function and hypertrophic growth. PAR actions may assume clinical importance in the border zone surrounding an infarction, where local proteolysis of PARs by serine proteases generated during inflammatory or thrombogenic pathways would elevate calcium concentration (setting the stage for arrhythmias), promote hypertrophic growth, and/or influence cardiomyocyte survival.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10827135     DOI: 10.1161/01.res.86.10.1054

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  44 in total

Review 1.  Protein kinase C isoform-selective signals that lead to cardiac hypertrophy and the progression of heart failure.

Authors:  Abdelkarim Sabri; Susan F Steinberg
Journal:  Mol Cell Biochem       Date:  2003-09       Impact factor: 3.396

2.  Protease-activated receptor 2 deficiency reduces cardiac ischemia/reperfusion injury.

Authors:  Silvio Antoniak; Mauricio Rojas; Denise Spring; Tara A Bullard; Edward D Verrier; Burns C Blaxall; Nigel Mackman; Rafal Pawlinski
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-08-19       Impact factor: 8.311

Review 3.  Proteinase-activated receptors in the lower urinary tract.

Authors:  James D Moffatt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-02-10       Impact factor: 3.000

Review 4.  Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more.

Authors:  R Ramachandran; M D Hollenberg
Journal:  Br J Pharmacol       Date:  2007-12-03       Impact factor: 8.739

5.  Effects of thrombin and thrombin receptor activation on cardiac function after acute myocardial infarction.

Authors:  Xinyuan Gu; Xiaorong Zhang; Guihua Lu; Yanhui Li; Xiujuan Li; He Huang; Jianping Zeng; Lilong Tang
Journal:  Am J Transl Res       Date:  2015-04-15       Impact factor: 4.060

6.  Protease-activated receptor 1 activation enhances doxorubicin-induced cardiotoxicity.

Authors:  Silvio Antoniak; Kohei Tatsumi; Clare M Schmedes; Steven P Grover; Rafal Pawlinski; Nigel Mackman
Journal:  J Mol Cell Cardiol       Date:  2018-08-10       Impact factor: 5.000

Review 7.  Straight to the heart: Pleiotropic antiarrhythmic actions of oral anticoagulants.

Authors:  Anke C Fender; Reza Wakili; Dobromir Dobrev
Journal:  Pharmacol Res       Date:  2019-05-02       Impact factor: 7.658

8.  Molecular mechanism of c-jun antisense gene transfection in alleviating injury of cardiomyocytes treated with burn serum and hypoxia.

Authors:  Yuesheng Huang; Angeng Hu
Journal:  World J Surg       Date:  2004-09-29       Impact factor: 3.352

9.  Protease activated receptors in cardiovascular function and disease.

Authors:  Junor A Barnes; Shamjeet Singh; Aldrin V Gomes
Journal:  Mol Cell Biochem       Date:  2004-08       Impact factor: 3.396

10.  Evidence that protease activated receptor 2 expression is enhanced in human coronary atherosclerotic lesions.

Authors:  C Napoli; F de Nigris; J L Wallace; M D Hollenberg; G Tajana; G De Rosa; V Sica; G Cirino
Journal:  J Clin Pathol       Date:  2004-05       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.